Aeon Biopharma Inc's Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical market, focusing on the development of ABP-450 as a full-label biosimilar to Botox®. Its primary market segment is the injectable botulinum toxin pharmaceutical market for therapeutic use. Competitors include Botox®, Dysport®, Xeomin®, and Daxxify®. Botox® is approved for twelve indications, including chronic migraine, cervical dystonia, blepharospasm, strabismus, overactive bladder, adult and pediatric detrusor overactivity, adult and pediatric upper and lower spasticity, and axillary hyperhidrosis. Dysport®, Xeomin®, and Daxxify® have more limited FDA-approved labels. The company also faces competition from botulinum toxins developed or commercialized in the United States, European Union, Asia, South America, and other markets, including topical botulinum toxins for therapeutic indications. The industry is subject to regulation by the FDA and other authorities.
AEON Biopharma Shifts Strategic Focus: Pioneers Biosimilar Pathway for ABP-450 with Proactive Phase 3 Trials and Promising Results AEON Biopharma is set to recalibrate its strategic direction toward developing biosimilars with a focused effort on ABP-450 through a 351(k) pathway. Scheduled to initiate a head-to-head comparative Phase 3 study with BOTOX® for cervical dystonia (CD) in Q3 2024, AEON shows promising preliminary results. Additionally, AEON has delivered encouraging clinical and preclinical data on ABP-450 not only for CD but also for Post-Traumatic Stress Disorder (PTSD). This article delves into the strategic realignment, clinical data, and the potential impact of ABP-450 as a biosimilar. Stra...
In an exciting development for the field of migraine treatment, AEON Biopharma recently announced its fourth quarter and full year 2023 financial results along with a successful end-of-Phase 2 meeting with the FDA. The company s proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraines have now received alignment on design and endpoints, further fueling hopes for a breakthrough treatment. This article delves into the significance of AEON Biopharma s achievements, the potential impact on migraine patients, and the implications for the pharmaceutical industry.Understanding the Burden of Migraines:Migraine is a debilitating neurological condition affecting millions worl...
Aeon Biopharma Inc’s Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical market, focusing on the development of ABP-450 as a full-label biosimilar to Botox®. Its primary market segment is the injectable botulinum toxin pharmaceutical market for therapeutic use. Competitors include Botox®, Dysport®, Xeomin®, and Daxxify®. Botox® is approved for twelve indications, including chronic migraine, cervical dystonia, blepharospasm, strabismus, overactive bladder, adult and pediatric detrusor overactivity, adult and pediatric upper and lower spasticity, and axillary hyperhidrosis. Dysport®, Xeomin®, and Daxxify® have more limited FDA-approved labels. The company also faces competition from botulinum toxins developed or commercialized in the United States, European Union, Asia, South America, and other markets, including topical botulinum toxins for therapeutic indications. The industry is subject to regulation by the FDA and other authorities.
Sources:
Aeon Biopharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aeon Biopharma inc’s corporate clients.
For your research, we’ve provided 9 tables on Aeon Biopharma inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
